<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693962</url>
  </required_header>
  <id_info>
    <org_study_id>OAIC 868/17</org_study_id>
    <nct_id>NCT04693962</nct_id>
  </id_info>
  <brief_title>FGF23 as a Marker of Acute Kidney Injury</brief_title>
  <official_title>Fibroblast Growth Factor-23 as a Marker of Acute Kidney Injury After Partial Nephrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A partial nephrectomy (PN) preserves renal parenchyma with a proper oncology outcome. PN is&#xD;
      performed during transitory ischemia to avoid massive bleeding during tumor resection.&#xD;
      Nevertheless, the transitory ischemia might cause an acute kidney injury(AKI). AKI diagnose&#xD;
      is based on the increase in plasma creatinine concentration and a decrease in urine output.&#xD;
      However, both plasma creatinine concentration and diuresis are useful for the diagnose, but&#xD;
      not in the detection of the risk patients. Therefore, there is considerable interest to find&#xD;
      a biomarkers of kidney injury that allow clinicians to predict the development of AKI. Hence,&#xD;
      we propose Fibroblastic Growth Factor-23 (FGF23) as a novel early biomarker to detect&#xD;
      patients in risk to develop postoperative AKI after a PN.&#xD;
&#xD;
      We will conduct an observational and prospective study in three different groups of patients:&#xD;
      PN gropup, patients who underwent PN with a transient and controlled renal ischemia injury&#xD;
      using a renal artery clamping; Hemicolectomy (HC) group, patients as non-renal ischemia&#xD;
      surgery controls, with similar demographic characteristics, but submitted to HC; and&#xD;
      Nephrolithotomy (NL) group, patients who underwent NL, as a control of kidney surgery with&#xD;
      physical injury.&#xD;
&#xD;
      In each patient, a time curve of plasmatic creatinine, blood urea nitrogen (BUN), and FGF23&#xD;
      were measure.&#xD;
&#xD;
      Our study aims to describe the role of FGF23 as an early biomarker of AKI after PN, where&#xD;
      patients are exposed to a controlled ischemic injury.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>72 hours</time_frame>
    <description>Patients that develop postoperative acute kidney injury</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Kidney Ischemia</condition>
  <arm_group>
    <arm_group_label>Partial Nephrectomy (PN)</arm_group_label>
    <description>Patients that will undergo PN with a transient and controlled renal ischemia injury using a renal artery clamping.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemicolectomy (HC)</arm_group_label>
    <description>Patients who will undergo HC, as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nephrolithotomy (NL)</arm_group_label>
    <description>Patients who undergo NL as non-renal ischemia surgery controls but with kidney physical injury</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Plasmatic Fibroblast Growth Factor-23 by means of ELISA</intervention_name>
    <description>Plasma levels of FGF-23 will be measured by ELISA</description>
    <arm_group_label>Hemicolectomy (HC)</arm_group_label>
    <arm_group_label>Nephrolithotomy (NL)</arm_group_label>
    <arm_group_label>Partial Nephrectomy (PN)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with a diagnose that requires any of three surgerys: Partial Nephrectomy,&#xD;
        Hemicolectomy, Nephrolithotomy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiology physical status (ASA) I or II.&#xD;
&#xD;
          -  Normal preoperative plasma creatinine level&#xD;
&#xD;
          -  Baseline estimated glomerular filtration rate (eGFR) &gt; 60 ml/min per 1.73 m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of chronic kidney disease&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Alterations in the parathormone or vitamin D axis&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Subjects with concomitant use of nephrotoxic drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Clinic Universidad de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas J Valls, MD</last_name>
      <phone>+56933741332</phone>
      <email>nvallsj@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chile</investigator_affiliation>
    <investigator_full_name>Nicolas Valls Jimenez</investigator_full_name>
    <investigator_title>MD, MSc</investigator_title>
  </responsible_party>
  <keyword>Acute kidney injury</keyword>
  <keyword>Creatinine</keyword>
  <keyword>Fibroblast Growth Factor-23</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

